Literature DB >> 1634750

Angelman syndrome: clinical profile.

R T Zori1, J Hendrickson, S Woolven, E M Whidden, B Gray, C A Williams.   

Abstract

To further delineate the clinical and developmental features of Angelman syndrome, we collected data through three sources of information: (1) physical examinations; (2) laboratory data and family questionnaire data of affected individuals; and (3) literature review. The questionnaire data describes a generally normal prenatal and birth history. Feeding difficulties, developmental delay, or seizures were the presenting problems in all infants. The diagnosis of Angelman syndrome, however, was not made in any infant prior to 1 year of age. Except for seizures, no medical or surgical complication was common, although a variety of visual complaints or findings were common. Sixty percent of Angelman syndrome children had a cytogenetically demonstrated deletion of chromosome 15q11-q13. The individuals with and without a deletion could not be differentiated clinically. Diagnosis in early childhood is therefore difficult, and a high index of suspicion is recommended.

Entities:  

Mesh:

Year:  1992        PMID: 1634750     DOI: 10.1177/088307389200700307

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  15 in total

1.  A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome.

Authors:  Lynne M Bird; Wen-Hann Tan; Carlos A Bacino; Sarika U Peters; Steven A Skinner; Irina Anselm; Rene Barbieri-Welge; Astrid Bauer-Carlin; Jennifer K Gentile; Daniel G Glaze; Lucia T Horowitz; K Naga Mohan; Mark P Nespeca; Trilochan Sahoo; Dean Sarco; Susan E Waisbren; Arthur L Beaudet
Journal:  Am J Med Genet A       Date:  2011-10-14       Impact factor: 2.802

Review 2.  Angelman syndrome (AS, MIM 105830).

Authors:  Griet Van Buggenhout; Jean-Pierre Fryns
Journal:  Eur J Hum Genet       Date:  2009-05-20       Impact factor: 4.246

Review 3.  Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion.

Authors:  A Smith; C Wiles; E Haan; J McGill; G Wallace; J Dixon; R Selby; A Colley; R Marks; R J Trent
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

4.  Angelman syndrome resulting from UBE3A mutations in 14 patients from eight families: clinical manifestations and genetic counselling.

Authors:  A Moncla; P Malzac; M O Livet; M A Voelckel; J Mancini; J C Delaroziere; N Philip; J F Mattei
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

5.  Parental view of epilepsy in Angelman syndrome: a questionnaire study.

Authors:  M Ruggieri; M A McShane
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

6.  Molecular and Clinical Aspects of Angelman Syndrome.

Authors:  A Dagli; K Buiting; C A Williams
Journal:  Mol Syndromol       Date:  2011-07-28

7.  Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid.

Authors:  Sarika U Peters; Lynne M Bird; Virginia Kimonis; Daniel G Glaze; Lina M Shinawi; Terry Jo Bichell; Rene Barbieri-Welge; Mark Nespeca; Irina Anselm; Susan Waisbren; Erica Sanborn; Qin Sun; William E O'Brien; Arthur L Beaudet; Carlos A Bacino
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

Review 8.  Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms.

Authors:  Renzo Guerrini; Romeo Carrozzo; Roberta Rinaldi; Paolo Bonanni
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Case report: Angelman syndrome in an individual with a small SMC(15) and paternal uniparental disomy: a case report with reference to the assessment of cognitive functioning and autistic symptomatology.

Authors:  Russell John Thompson; Patrick F Bolton
Journal:  J Autism Dev Disord       Date:  2003-04

10.  Normal social seeking behavior, hypoactivity and reduced exploratory range in a mouse model of Angelman syndrome.

Authors:  Melody Allensworth; Anand Saha; Lawrence T Reiter; Detlef H Heck
Journal:  BMC Genet       Date:  2011-01-14       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.